The HER-2/neu oncogene encodes a transmembrane receptor protein that is structurally related to the epidermal growth factor receptor (Coussens et al., 1985) . HER-2 is overexpressed in approximately one third of the primary breast carcinomas (Press et al., 1993) , and its increased expression is correlated with an adverse prognosis and a decreased overall and diseasefree survival (Slamon et al., 1987; Ross and Fletcher, 1998) . HER-2 overexpression has been demonstrated to enhance proliferative, metastatic and prosurvival signals in breast cancer cell lines (Hung et al., 1992; Ignatoski et al., 2000) and to induce resistance to hormonal therapy, paclitaxel and TNFa (Hudziak et al., 1988; Hung et al., 1992; Yu et al., 1998) . Moreover, an anti-HER-2 monoclonal antibody, trastuzumab, displays clinical activity either alone or in combination with chemotherapy in HER-2-expressing breast cancers (Hudziak et al., 1989; Baselga et al., 1998 Baselga et al., , 1999 Pegram et al., 1998 Pegram et al., , 1999 .
A link between HER-2 signalling and cyclooxygenase-2 (COX-2) expression has been recently established. Besides a coexpression in different tumor types, several reports showed indeed that HER-2 overexpression or activation increased the COX-2 gene transcription (Vadlamudi et al., 1999; Kiguchi et al., 2001) . Recent data suggested that this regulation occurred through a MAPK-dependent pathway .
COX-2 is an inducible enzyme that catalyses the synthesis of prostaglandins, prostacyclins and thromboxanes. COX-2 is expressed in transformed cells (Kutchera et al., 1996; Subbaramaiah et al., 1996) and in malignant tissues. It plays a major role in carcinogenesis since it has been demonstrated that enhanced synthesis of COX-2-derived prostaglandins (PGs) favors tumor growth by stimulating proliferation , angiogenesis , invasiveness (Tsujii et al., 1997) and by inhibition of apoptosis (Tsujii and DuBois, 1995; Sheng et al., 1998) . Moreover, selective COX-2 inhibitors reduce the formation and growth of experimental tumors (Sheng et al., 1997; Kawamori et al., 1998; Sawaoka et al., 1998; Harris et al., 2000) as well as the number of intestinal tumors in Familial Adenomatous Polyposis patients (Steinbach et al., 2000) . Direct cause-and-effect relationship between COX-2 and tumorigenesis has also been established. COX-2-null mice were protected against development of intestinal and skin tumors (Oshima et al., 1996; Tiano et al., 2002) . Moreover, a recent study demonstrated that COX-2 forced expression in murine mammary gland was sufficient to induce breast cancer in multiparous animals (Liu et al., 2001) . Finally, COX-2 overexpression was observed in tumors from MMTV/ neu mice, and its inhibition with celecoxib reduced the incidence of mammary tumors in this model (Howe et al., 2002) .
Taken together, there is growing evidence that COX-2 may thus play an important role in mediating HER-2-induced mammary tumor formation. This led us to study the tight interrelations between those two proteins, and to investigate whether HER-2 synthesis could also be regulated by COX-2 in MCF7 A/Z and T47D cells, two breast cancer cell lines.
To test this hypothesis, we first determined the influence of COX-2 transient expression on the HER-2 promoter. Increasing amounts of COX-2 expression vector were transfected in MCF7 A/Z mammary adenocarcinoma cells in the presence of an HER-2 proximal promoter reporter construct, p756LUC (Grooteclaes et al., 1994) . Luciferase activity was induced in a dose-response manner ( Figure 1a) . We then assessed HER-2 mRNA levels in response to COX-2 ectopic expression. We established a stably transfected MCF7 A/Z cell line expressing COX-2 protein in the presence of tetracycline. This tetracycline-inducible cell line was named 'MCF7 ind'. HER-2-specific quantitative real-time PCR revealed that inducible COX-2 expression led to increased HER-2 mRNA levels, whereas tetracycline had no effect on HER-2 expression in MCF7 A/Z control cells ( Figure 1b ). Western blotting demonstrated that transient COX-2 expression in MCF7 A/Z and T47D cell lines enhanced HER-2 protein levels, whereas transfection of an empty vector did not (Figure 1c ). These data clearly indicated that COX-2 induced HER-2 mRNA and protein expression.
As prostaglandin E2 (PGE2) is a major product of COX-2 enzymatic activity, we studied the PGE2 effect on HER-2 expression. A luciferase assay demonstrated that increasing amounts of PGE2 induced HER-2 proximal promoter transcriptional activity in a dosedependent way (Figure 2a ). HER-2-specific real-time PCR and western blotting further showed that PGE2 treatment also led to increased endogenous HER-2 mRNA and protein levels (Figure 2b and c) . Taken together, these results strongly suggested that COX-2 activity increased HER-2 expression via its enzymatic product PGE2, but cannot rule out that other products are released in response to COX-2 activity and also influence the HER-2 promoter. The PGE2 prostaglandin is known to induce the cAMP signalling pathway. We observed that PGE2-induced HER-2 expression can be specifically blocked after cellular interaction with cAMP response element (CRE) decoys oligonucleotides (Benoit et al., unpublished results). However, these experiments remain preliminary and the PGE2-induced signalling pathways leading directly or indirectly to HER-2 gene expression need to be further explored.
To test the biological significance of these observations, the MDA-MB-231 cells were treated with 5 mg) , an RSV-bGAL plasmid (0.4 mg) and indicated amounts of COX-2 expression plasmid (a generous gift of Prof KKWu, Houston, TX, USA). Total amount of DNA was kept constant by addition of an empty pcDNA3 plasmid. At 6 h after transfection, arachidonic acid (10mM), the limitative COX-2 enzymatic substrate, was added in the medium. After 24 h, cells were lyzed, luciferase activity was determined with the Luciferase Reporter Gene Assay kit and bGalactosidase activity was assessed with the chemoluminescent bGal Reporter Gene Assay Kit (Roche, Mannheim, Germany). Luciferase activities were standardized with bGal activities and expressed as fold induction relative to the activity observed with the reporter plasmid alone. All the transfections were realized with FuGENE (Roche). (b) Control (hatched boxes) or COX-2 inducible (black boxes) MCF7 A/Z cells were treated for 48 h with tetracycline (1 mg/ml) in the presence of arachidonic acid (10 mM). Quantitative real-time PCR was performed using HER-2-specific oligonucleotides and GAPDH as internal control. The quantitative PCR reaction samples involved 2 ml of 20 Â diluted cDNAs, 2 ml of 10 Â SYBR Green PCR mix buffer, 1.6 ml MgCl 2 , 25 mM and 7 mM of each primer. Quantification was performed with the Light Cycler PCR Technology (Roche, Mannheim, Germany). The primer sequences were as follow: GAPDH: 5 0 -ATGGGGAAGGT-GAAGGTGGTC-3 0 and 5 0 -TGATGGCATGGACTGTGG-3 0 ; HER-2: 5 0 -AGACGAAGCATACGTGA-3 0 and 5 0 -GTAC-GAGCCGCACATC-3 0 . (c) MCF7 A/Z and T47D breast adenocarcinoma cells were transfected either with pcDNA3 (À) or COX-2 expression ( þ ) plasmid. At 24 h after transfection, cells were lyzed in SDS 1%, and 10 mg of total cellular extract were analysed by Western blotting using HER-2 (Upstate Biology, Lake Placid, UK) and bActin (Sigma, Bornem, Belgium)-specific antibodies. Arrows indicate HER2-and bActin-specific bands. The T47D cells were obtained from ATCC COX-2 and PGE2 regulate HER-2 transcription V Benoit et al celecoxib, a specific COX-2 inhibitor, widely used in arthritis treatment. Western blotting experiment was then carried out and revealed that COX-2 inhibition completely blocked HER-2 expression (Figure 3a) . In order to test the putative pharmacological applications of these observations, the MCF7 A/Z breast cancer cells stably transfected with an inducible COX-2 expression vector (MCF7 ind) were pretreated in vitro with celecoxib, trastuzumab or a combination of both compounds before incubation with the cytotoxic agent daunomycine, a topoisomerase II inhibitor commonly used in the treatment of various human cancers. MCF7 A/Z cells that do not express COX-2 respond poorly to celecoxib either alone or in combination with daunomycin or daunomycin plus trastuzumab (data not shown). However, when COX-2 expression is induced in the MCF7 A/Z ind clone, celecoxib or trastuzumab reproducibly increased the daunomycin cytotoxic effect (Figure 3b) . Moreover, when both inhibitors were simultaneously used to pretreat the cells before daunomycin addition, an additive effect was observed and the three drug combination therefore displayed the most efficient cytotoxicity. The same experiment was performed in MDA-MB-231 breast cancer cells that express COX-2 as well as moderate levels of HER-2. In these cells, similar data were obtained as celecoxib and trastuzumab individually increased daunomycin cytotoxicity, while a better effect was observed when both inhibitors were combined (data not shown).
Our data thus clearly demonstrate for the first time that COX-2 positively regulates HER-2 expression, through PGE2 production, and that COX-2 inhibition leads to a decreased HER-2 expression and to an . In total, 10 mg of total cellular extract was analysed by Western blotting as described in Figure 1 . Arrows indicate HER-2-and bActin-specific bands. (b) MCF7 ind cells, where COX-2 expression was induced by tetracyclin treatment, were left untreated or were pretreated for 48 h with trastuzumab (1 mM), celecoxib (10 mM) or both before a 24 h daunomycin stimulation. Cell viability was assessed by a colorimetric assay (WST-1, Roche) and expressed as percentage of the control COX-2 and PGE2 regulate HER-2 transcription V Benoit et al improved cell sensitivity to daunomycin. As it has been previously demonstrated that HER-2 activated COX-2 synthesis (Vadlamudi et al., 1999; Kiguchi et al., 2001; Subbaramaiah et al., 2002) , we, therefore, propose an original model where HER-2 and COX-2 transcriptionally regulate each other in a positive loop (Figure 4) . This interrelation could be a new mechanism explaining the marked resistance of HER-2-overexpressing cells to antineoplasic therapies. Based on the expression of both proteins in some cancers, previous reports already suggested a benefit for combined HER-2 and COX-2 inhibition in the treatment of cholangiocarcinoma (Sirica et al., 2002) and colon cancers (Mann et al., 2001) . We provide here additional support for coupling classic chemotherapy with COX-2 and HER-2 inhibitors.
It would also be most interesting to determine whether a similar effect could be observed with other receptors belonging to the EGFR family. Recent data showed that PGE2 activated EGF receptor by phosphorylation and triggers the subsequent mitogenic signalling pathway (Pai et al., 2002) , but further experiments are required to establish the role of COX-2 and PGs on EGFR. Figure 4 A model for HER-2 and COX-2 interactions. HER-2 expression is known to induce COX-2 expression through the Ras/ MAPK/AP-1 pathway. In this report, we demonstrate that COX-2 can in turn stimulate HER-2 expression through its major product, PGE2. Selective COX-2 inhibitors, such as celecoxib, can disrupt this positive loop COX-2 and PGE2 regulate HER-2 transcription V Benoit et al
